Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 3:02 pm Sale | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | FEDERATED HERMES INC. FHI | 3,986,870 5.850% | -293,658 (-6.86%) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 11,525,089 16.900% | 2,054,597 (+21.69%) | Filing History |
| 2022-02-11 11:19 am Sale | 2022-02-14 | 13G | Ultragenyx Pharmaceutical Inc. RARE | Capital International Investors | 5,629,453 8.300% | -1,270,040 (-18.41%) | Filing History |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | VANGUARD GROUP INC | 5,920,568 8.690% | 270,183 (+4.78%) | Filing History |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 3,484,652 5.100% | -1,802,824 (-34.10%) | Filing History |
| 2021-10-26 4:44 pm Sale | 2021-10-21 | 13D | Arcturus Therapeutics Holdings Inc. ARCT | Ultragenyx Pharmaceutical Inc. RARE | 1,200,000 4.600% | -200,000 (-14.29%) | Filing History |
| 2021-10-08 2:08 pm Sale | 2021-10-12 | 13G | Ultragenyx Pharmaceutical Inc. RARE | Capital Research Global Investors | 3,361,792 5.000% | -3,900,109 (-53.71%) | Filing History |
| 2021-08-12 5:09 pm Sale | 2021-08-10 | 13D | Arcturus Therapeutics Holdings Inc. ARCT | Ultragenyx Pharmaceutical Inc. RARE | 1,400,000 5.300% | -800,000 (-36.36%) | Filing History |
| 2021-02-16 4:04 pm Purchase | 2021-02-16 | 13G | Ultragenyx Pharmaceutical Inc. RARE | Capital International Investors | 6,899,493 10.500% | 304,831 (+4.62%) | Filing History |
| 2021-02-16 1:24 pm Sale | 2021-02-16 | 13G | Ultragenyx Pharmaceutical Inc. RARE | Capital World Investors | 3,129,724 4.700% | -107,571 (-3.32%) | Filing History |
| 2021-02-16 1:16 pm Purchase | 2021-02-16 | 13G | Ultragenyx Pharmaceutical Inc. RARE | Capital Research Global Investors | 7,261,901 11.000% | 899,206 (+14.13%) | Filing History |
| 2021-02-16 12:23 pm Purchase | 2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 9,470,492 14.300% | 2,851,572 (+43.08%) | Filing History |
| 2021-02-12 1:06 pm Purchase | 2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | FEDERATED HERMES INC. FHI | 4,280,528 6.470% | 1,308,520 (+44.03%) | Filing History |
| 2021-02-10 11:57 am Purchase | 2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | VANGUARD GROUP INC | 5,650,385 8.570% | 797,226 (+16.43%) | Filing History |
| 2021-02-01 08:30 am Purchase | 2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 5,287,476 8.000% | 554,392 (+11.71%) | Filing History |
| 2020-12-10 4:51 pm Sale | 2020-12-08 | 13D | Arcturus Therapeutics Holdings Inc. ARCT | Ultragenyx Pharmaceutical Inc. RARE | 2,200,000 9.000% | -800,000 (-26.67%) | Filing History |
| 2020-11-06 4:16 pm Purchase | 2020-10-22 | 13D | Solid Biosciences Inc. SLDB | Ultragenyx Pharmaceutical Inc. RARE | 521,720 14.500% | 521,720 (New Position) | Filing History |
| 2020-05-22 5:21 pm Purchase | 2020-05-20 | 13D | Arcturus Therapeutics Holdings Inc. ARCT | Ultragenyx Pharmaceutical Inc. RARE | 3,000,000 14.600% | 321,964 (+12.02%) | Filing History |